Skip to main content
Fig. 6 | BMC Research Notes

Fig. 6

From: Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma

Fig. 6

Kaplan–Meier analysis of overall survival in small cohort of patients with non-measurable lesions by mRECIST (n = 16). The log-rank test showed significant differences between progressive disease (PD) (n = 8) and stable disease (SD) groups (n = 8) as determined by RECIST 1.1 (P = 0.0312)

Back to article page